North of Tyne

TA489 Vismodegib for treating basal cell carcinoma The formulary will reflect the NICE Guidance TA490 Nivolumab for treating squamous cell carcinoma of the head and neck after platinum-based chemotherapy The formulary will reflect the NICE Guidance TA491 Ibrutinib for treating Waldenstrom’s macroglobulinaemia ................
................